Japonia - japoński - すりの適正使用協議会 RAD-AR Council, Japan

日医工株式会社 - ファモチジン - 白〜淡黄白色の口腔内崩壊用の錠剤、直径8.0mm、厚さ3.4mm - 胃粘膜のヒスタミン₂受容体を遮断し、胃酸分泌やペプシン分泌をおさえて、潰瘍が起こるのを抑えます。
通常、胃潰瘍や十二指腸潰瘍などの治療、胃炎の急性増悪期の胃粘膜病変（びらん、出血、発赤、浮腫）の改善に用いられます。

Japonia - japoński - すりの適正使用協議会 RAD-AR Council, Japan

日医工株式会社 - ファモチジン - 白〜淡黄白色の口腔内崩壊用の錠剤、直径8.5mm、厚さ3.5mm - 胃粘膜のヒスタミン₂受容体を遮断し、胃酸分泌やペプシン分泌をおさえて、潰瘍が起こるのを抑えます。
通常、胃潰瘍や十二指腸潰瘍などの治療、胃炎の急性増悪期の胃粘膜病変（びらん、出血、発赤、浮腫）の改善に用いられます。

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

physicians total care, inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine is indicated in: 1. short-term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short-term treatment of patients with symptoms of gerd (see  clinical pharmacology in adults, clinical studies).  famotidine is also indicated for the short-term treatment of esophagitis

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine is indicated in: 1.short-term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short-term treatment of patients with symptoms of gerd (see  clinical pharmacology in adults, clinical studies).  famotidine is also indicated for the short-term treatment of esophagitis

Japonia - angielski - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - famotidine - white to pale yellowish white oral disintegrant tablet, φ: 8.0 mm, thickness: 3.4 mm

Japonia - angielski - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - famotidine - white to pale yellowish white oral disintegrant tablet, φ: 8.5 mm, thickness: 3.5 mm